The groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The two-day event will showcase achievements and address issues pertaining to the industry
The fund has already invested in seven companies including Medikabazaar, THB, Impact Guru, Stanplus, Ekincare, Qure.ai and HealthifyMe
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
All of Us Research Program releases genomic data to researchers, combined with participant-generated data collected on Vibrent Health’s research platform
As the Covid-19 pandemic continues to have a disproportionate impact on women, Organon issues a call to action for other leaders to create opportunities to focus on women’s health
Subscribe To Our Newsletter & Stay Updated
